IBO — Universal Ibogaine Income Statement
0.000.00%
Last trade - 00:00- CA$3.09m
- CA$5.39m
- CA$1.03m
- 11
- 46
- 27
- 18
Annual income statement for Universal Ibogaine, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st | 2023 July 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 1.07 | 1.03 |
| Cost of Revenue | ||
| Gross Profit | 0.497 | -0.028 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 9.23 | 2.97 |
| Operating Profit | -8.15 | -1.94 |
| Total Net Non Operating Interest Income / Expense | ||
| Gain / Loss on Sale of Assets | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -10.5 | -2.39 |
| Net Income After Taxes | -10.5 | -2.39 |
| Net Income Before Extraordinary Items | ||
| Net Income | -10.5 | -2.39 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -10.5 | -2.39 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.027 | -0.011 |